SYNCHRONICITY Phase 4 Data: Modest Efficacy Signal Meets High HTA Bar in Crowded Corticosteroid Implant Field

ANI Pharmaceuticals Reports Positive SYNCHRONICITY Trial Data for Chronic NIU-PS

ANI Pharmaceuticals announced positive six-month topline data from its Phase 4, open-label, single-arm SYNCHRONICITY trial evaluating Fluocinolone Acetonide Intravitreal Implant in 108 patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS). The trial met both co-primary endpoints with statistical significance. Patients gained a mean of +3.6 letters in best corrected visual acuity (BCVA) (p<0.0077) and experienced a mean reduction of -157.5 microns in central subfield thickness (CST) (p<0.0001) at six months. Safety findings were consistent with previous trials, with ocular hypertension and cataract being the most common adverse events.

• The SYNCHRONICITY trial successfully achieved both co-primary endpoints at six months. Patients demonstrated a statistically significant mean improvement of +3.6 letters in best corrected visual acuity (BCVA) from a baseline of 62.5 letters, reaching 65.8 letters. Concurrently, central subfield thickness (CST) showed a significant mean reduction of -157.5 microns from a baseline of 505.7 microns, decreasing to 348.8 microns.
• The safety profile observed in the SYNCHRONICITY trial for Fluocinolone Acetonide Intravitreal Implant was consistent with findings from prior studies. The most frequently reported treatment-related adverse events included ocular hypertension in 6% of patients and cataract in 5% of patients. A notable 18% of patients experienced an IOP increase of ≥25 mmHg, with 7% requiring laser or surgical intervention.
• SYNCHRONICITY was a Phase 4, open-label, single-arm study conducted in the U.S. involving 108 patients with chronic non-infectious uveitis affecting the posterior segment of the eye who had previously responded to steroid therapy. The study aimed to provide real-world data on the inflammatory control offered by the 0.18 mg implant, with full results anticipated for presentation at medical conferences in Q4 2026.

Addressing Unmet Needs in Chronic NIU-PS Treatment

Chronic NIU-PS presents a particularly complex therapeutic landscape, where the burden of disease extends beyond inflammation control to encompass treatment-related complications, inadequate long-term remission, and significant evidence gaps. Despite advances in immunosuppressive and biologic therapies, a substantial proportion of patients continue to experience persistent or recurrent disease with cumulative structural ocular damage.

• Weak clinical evidence base: A persistent limitation across the literature is the lack of randomized controlled trials for immunosuppressive treatments in severe noninfectious uveitis, with available data frequently derived from small retrospective studies without control populations. The variable natural course of uveitis further confounds efficacy assessment across study designs.

• Corticosteroid dependency and long-term unsuitability: Corticosteroids remain the cornerstone of acute management but are inappropriate for long-term use due to their adverse effect profile. If inflammatory activity is not controlled within 6 weeks, or if the required corticosteroid dose is unacceptably high, escalation to immunomodulatory therapy is necessitated.

• Incomplete disease control and low remission rates: Complete control of inflammatory activity with immunomodulatory drugs and biologics is achieved in only 65–80% of cases, leaving 20–35% of patients without adequate disease control. Remission—defined as absence of inflammation without any treatment—is achieved in fewer than 20% of patients, underscoring the chronic and often lifelong nature of this condition.

• High risk of sight-threatening ocular complications: Patients with noninfectious intermediate, posterior, or panuveitis carry a 5-year risk of 66% for any ocular complication versus 24% in controls, with specific risks including cataract (35% vs. 13%), retinal disorder (28% vs. 2%), glaucoma (20% vs. 9%), visual disturbance (29% vs. 9%), retinal detachment (11% vs. 0.8%), and blindness or low vision (5% vs. 0.5%). Hazard ratios confirm markedly elevated risk: HR 5.2 for any ocular complication, HR 4.8 for visual disturbance, HR 3.2 for cataract, and HR 2.7 for glaucoma (all P < 0.001).

• Treatment-related ocular complications: Therapeutic interventions themselves carry significant complication risk. For moderate-to-severe NIU, the estimated incidence of glaucoma drug prescriptions was 106 per 1,000 person-years at year 1, declining to 73 and 52 per 1,000 person-years at years 2 and 5, respectively—with the highest complication burden concentrated in the first year of treatment. Fluocinolone acetonide implant therapy was associated with significantly increased rates of cataract (HR 3.0; P = 0.0001), cataract surgery (HR 3.8; P < 0.0001), intraocular pressure elevation (HR range 3.7–5.6), and glaucoma (26.3% vs. 10.2% by 48 months; HR 3.0; P = 0.0002) compared with systemic therapy.

• Limitations of biologic therapies: TNF-α antagonists, the most widely used biologic class, are associated with high cost and demonstrate potentially greater efficacy in rheumatologic and non-ocular autoimmune conditions than in uveitis specifically. Furthermore, anti-TNF monoclonal antibodies are contraindicated in patients with demyelinating disorders, limiting their applicability in MS-associated uveitis. Long-term efficacy and safety data for newer biologic agents remain insufficient.

• Surgical complexity in the context of active disease: Uveitic eyes undergoing surgical intervention, such as phacotrabeculectomy with mitomycin C, demonstrate significantly lower IOP control success rates compared to non-uveitic controls (91.3% at one year, 84.8% at two years; P = 0.0423), largely attributable to postoperative inflammation recurrence. Favorable surgical outcomes are contingent upon at least 3 months of preoperative disease quiescence.

• Access and multidisciplinary management barriers: Patients with uveitis of non-rheumatic aetiology frequently require immunosuppression, a therapeutic modality not readily accessible within standard ophthalmology practice. Optimal management necessitates collaborative working between rheumatologists and ophthalmologists, a model that is not universally available or consistently implemented.

SYNCHRONICITY Trial: Positive Efficacy for Fluocinolone Acetonide Implant

Recent clinical evidence for chronic non-infectious uveitis affecting the posterior segment (chronic NIU-PS) spans a range of interventional strategies — from biologic TNF-α inhibition to intravitreal corticosteroid implants and combination immunomodulatory regimens. The studies below reflect both randomized trial data and real-world cohort findings published in 2025–2026, offering a multi-dimensional view of current therapeutic performance across efficacy and safety dimensions.

Safety Profile of Fluocinolone Acetonide Intravitreal Implant

The safety landscape for chronic NIU-PS therapies is shaped by a diverse set of treatment modalities, each carrying a distinct adverse event profile that clinicians must weigh against therapeutic benefit. Across clinical trials, both ocular and systemic safety signals have been consistently documented, with immunosuppressive burden and route of administration emerging as key determinants of tolerability.

• Adalimumab (anti-TNF-α): In a phase 3 trial (n=226), the most frequently reported adverse events were arthralgia (23% vs. 11% placebo), nasopharyngitis (16% vs. 17%), and headache (15% in both groups), with no opportunistic infections and one case of non-serious squamous cell carcinoma in the adalimumab arm. In Behçet's uveitis patients, adverse events occurred in 7 patients in the adalimumab group — predominantly upper respiratory tract infections (n=5) and gastrointestinal discomfort (n=2). Across broader NIU populations, adalimumab generated 9.40 events per patient-year versus 7.79 in the placebo group.

• Anti-drug antibodies (ADA-A) against adalimumab: ADA-A were detected in 5/81 patients (6.2%; 95% CI: 2.7–13.6) and were associated with higher BMI, elevated C-reactive protein, lower patient-reported health scores, and markedly reduced serum adalimumab levels (median 0.0 µg/mL vs. 5.0 µg/mL; p=0.002). Notably, no association was found between ADA-A presence and uveitis activity, visual acuity, or direct adverse effects to adalimumab.

• Interferon-alpha (IFN-α): This agent demonstrated a broad systemic adverse event burden, including tiredness, lymphopenia, flu-like symptoms, and transient hepatic enzyme elevation. Depression was observed in four patients — including one suicide attempt — and three patients developed IFN-α-associated retinopathy, which resolved upon dose reduction. This range of toxicities represents a meaningful constraint on clinical use.

• mTOR inhibitors (sirolimus and everolimus): Drug-related adverse event rates differed notably between agents: 0.640 events per patient-year for sirolimus versus 0.111 for everolimus. Reported events included ocular irritation, visual floaters, nausea, and vomiting, with both agents considered generally well tolerated, particularly via local administration. In a separate intravitreal sirolimus study (n=592), mean IOP changes from baseline were minimal across all treatment groups.

• Corticosteroids and traditional immunosuppressives: Long-term corticosteroid use is associated with significant systemic toxicity, limiting its appropriateness for chronic disease management. For intravitreal corticosteroid implants, cataract development is a clinically relevant concern that warrants pre-treatment counseling in phakic or younger patients, though adverse effects are considered manageable in most cases. Systemic corticosteroid discontinuation was achievable in 22% of uveitis patients receiving adalimumab versus 11% in those without.

• Repository corticotropin injection (RCI): Safety monitoring during RCI therapy should include vigilance for hyperglycemia and diabetic complications, with dose reduction or discontinuation indicated for severe or recurrent adverse events, excessive toxicity, or sustained remission of ≥2 years.

• Risk of infection reactivation with immunosuppression: Across immunosuppressive regimens, clinicians should remain alert to the risk of viral and mycobacterial reactivation. While most underlying chronic infections do not constitute absolute contraindications, appropriate pre-treatment screening and ongoing monitoring are essential to mitigate this risk.